terfenadine has been researched along with Torsade de Pointes in 59 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was designed to compare the proarrhythmic activity of the antimalarial drug, halofantrine and the antihistamine, terfenadine, with that of clofilium a K(+) channel blocking drug that can induce torsade de pointes." | 7.71 | Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. ( Batey, AJ; Coker, SJ, 2002) |
| "A 65-year-old woman with liver cirrhosis complicated by hepatocellular carcinoma lost consciousness due to torsades de pointes with prolongation of the QT-interval after 10 days of treatment with terfenadine." | 7.69 | Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. ( Adachi, Y; Kamisako, T; Nakagawa, H; Yamamoto, T, 1995) |
| " Recent clinical evidence shows that some of the early prototypes in this class, namely terfenadine and astemizole, have the potential for producing torsade de pointes, a rare form of ventricular arrhythmia that is life-threatening." | 7.69 | Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. ( del Prado, M; Egan, RW; Hey, JA; Kreutner, W, 1996) |
| "Terfenadine is a widely used antihistamine." | 5.29 | Torsade de pointes induced by terfenadine in a patient with long QT syndrome. ( Kim, SS; Koh, KK; Rim, MS; Yoon, J, 1994) |
| "It has been difficult to experimentally reproduce synergistic effects of ketoconazole on terfenadine-induced torsade de pointes." | 3.96 | Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes. ( Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A, 2020) |
| "For terfenadine, TRIaD predicts drug-induced proarrhythmia: with λ prolongation, Torsade de Pointes is preferred, otherwise ventricular tachycardia/ventricular fibrillation." | 3.77 | Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. ( De Clerck, F; Dujardin, K; Dumotier, B; Hoffmann, P; Hondeghem, LM, 2011) |
| " This study was designed to compare the proarrhythmic activity of the antimalarial drug, halofantrine and the antihistamine, terfenadine, with that of clofilium a K(+) channel blocking drug that can induce torsade de pointes." | 3.71 | Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. ( Batey, AJ; Coker, SJ, 2002) |
| "A 65-year-old woman with liver cirrhosis complicated by hepatocellular carcinoma lost consciousness due to torsades de pointes with prolongation of the QT-interval after 10 days of treatment with terfenadine." | 3.69 | Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. ( Adachi, Y; Kamisako, T; Nakagawa, H; Yamamoto, T, 1995) |
| " Recent clinical evidence shows that some of the early prototypes in this class, namely terfenadine and astemizole, have the potential for producing torsade de pointes, a rare form of ventricular arrhythmia that is life-threatening." | 3.69 | Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. ( del Prado, M; Egan, RW; Hey, JA; Kreutner, W, 1996) |
| "Fexofenadine HCl has been investigated more extensively for possible electrophysiological effects than any other antihistamine." | 2.69 | Cardiovascular safety of fexofenadine HCl. ( Ahlbrandt, R; Brown, AM; Mason, J; Pratt, C; Rampe, D; Reynolds, R; Russell, T, 1999) |
| "Ebastine also inhibit potassium channels, cloned human Kv 1." | 2.41 | [The effect of second generation histamine antagonists on the heart]. ( Górska, M; Grzelewska-Rzymowska, I; Pietrzkowicz, M, 2001) |
| " This paper reviews the pharmacokinetic properties of these second-generation agents and is intended to provide comparisons that help explain differences in dosing profiles and drug interactions for members of this class of drugs." | 2.40 | Pharmacokinetic overview of oral second-generation H1 antihistamines. ( Estes, KS; González, MA, 1998) |
| " The primary difference between traditional (first-generation) and nonsedating (second-generation) histamine1-receptor antagonists is the incidence and severity of adverse reactions." | 2.39 | Cardiovascular toxicity of antihistamines. ( Smith, SJ, 1994) |
| "Terfenadine has been reported to cause cardiac death." | 1.38 | Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? ( Gallacher, DJ; Hermans, AN; Lu, HR, 2012) |
| " This report describes the first case of TDP in a healthy patient taking the recommended therapeutic dosage of terfenadine." | 1.30 | Torsades de pointes with terfenadine ingestion. ( June, RA; Nasr, I, 1997) |
| "Terfenadine is a widely used antihistamine." | 1.29 | Torsade de pointes induced by terfenadine in a patient with long QT syndrome. ( Kim, SS; Koh, KK; Rim, MS; Yoon, J, 1994) |
| "Terfenadine metabolism was delayed by itraconazole, leading to an increased level of unmetabolised terfenadine." | 1.29 | Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. ( Neuvonen, P; Pohjola-Sintonen, S; Toivonen, L; Viitasalo, M, 1993) |
| " The lessons learned from the experiences with these drugs hold implications for the future development of agents that prolong the QT interval and suggest the need for dose-response relation data and metabolic evaluations to define the subpopulations at particular risk." | 1.29 | Is QT interval prolongation harmful? A regulatory perspective. ( Botstein, P, 1993) |
| "Torsades de pointes is a form of polymorphic ventricular tachycardia that is associated with prolongation of the QT interval." | 1.28 | Torsades de pointes occurring in association with terfenadine use. ( Cantilena, LR; Ferguson, CL; Killeavy, ES; Lloyd, BK; Monahan, BP; Troy, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (66.10) | 18.2507 |
| 2000's | 14 (23.73) | 29.6817 |
| 2010's | 5 (8.47) | 24.3611 |
| 2020's | 1 (1.69) | 2.80 |
| Authors | Studies |
|---|---|
| Pearlstein, R | 1 |
| Vaz, R | 1 |
| Rampe, D | 2 |
| Mirams, GR | 1 |
| Cui, Y | 1 |
| Sher, A | 1 |
| Fink, M | 1 |
| Cooper, J | 1 |
| Heath, BM | 1 |
| McMahon, NC | 1 |
| Gavaghan, DJ | 1 |
| Noble, D | 1 |
| Wiśniowska, B | 1 |
| Mendyk, A | 1 |
| Fijorek, K | 1 |
| Glinka, A | 1 |
| Polak, S | 1 |
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 2 |
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Hagiwara-Nagasawa, M | 1 |
| Kambayashi, R | 1 |
| Chiba, K | 1 |
| Nunoi, Y | 1 |
| Izumi-Nakaseko, H | 1 |
| Matsumoto, A | 1 |
| Sugiyama, A | 4 |
| Vos, MA | 1 |
| Dabhi, J | 1 |
| Mehta, A | 1 |
| Hondeghem, LM | 1 |
| Dujardin, K | 1 |
| Hoffmann, P | 1 |
| Dumotier, B | 1 |
| De Clerck, F | 2 |
| Lu, HR | 2 |
| Hermans, AN | 1 |
| Gallacher, DJ | 1 |
| Satoh, Y | 2 |
| Takahara, A | 2 |
| Nakamura, Y | 2 |
| Shimizu-Sasamata, M | 1 |
| Sato, S | 1 |
| Miyata, K | 1 |
| Hashimoto, K | 2 |
| Heist, EK | 1 |
| Ruskin, JN | 1 |
| Katchman, AN | 1 |
| Koerner, J | 1 |
| Tosaka, T | 1 |
| Woosley, RL | 3 |
| Ebert, SN | 1 |
| Ishida, Y | 1 |
| Wang, K | 1 |
| Roden, DM | 1 |
| Sisáková, M | 1 |
| Toman, O | 1 |
| Floriánová, A | 1 |
| Kadlecová, J | 1 |
| Chroust, K | 1 |
| Papousek, I | 1 |
| Spinar, J | 1 |
| Ciummo, PE | 1 |
| Katz, NL | 1 |
| Pinney, SP | 1 |
| Koller, BS | 1 |
| Franz, MR | 1 |
| Kamisako, T | 1 |
| Adachi, Y | 1 |
| Nakagawa, H | 1 |
| Yamamoto, T | 1 |
| Koh, KK | 1 |
| Rim, MS | 1 |
| Yoon, J | 1 |
| Kim, SS | 1 |
| Kelloway, JS | 1 |
| Pongowski, MA | 1 |
| Schoenwetter, WF | 1 |
| Smith, SJ | 1 |
| Matsis, PP | 1 |
| Easthope, RN | 1 |
| Paris, DG | 1 |
| Parente, TF | 1 |
| Bruschetta, HR | 1 |
| Guzman, E | 1 |
| Niarchos, AP | 1 |
| Pohjola-Sintonen, S | 3 |
| Gully, C | 1 |
| Riem, R | 1 |
| Biglin, KE | 1 |
| Faraon, MS | 1 |
| Constance, TD | 1 |
| Lieh-Lai, M | 1 |
| Viitasalo, M | 2 |
| Toivonen, L | 1 |
| Neuvonen, P | 2 |
| Botstein, P | 1 |
| Herings, RM | 1 |
| Stricker, BH | 1 |
| Leufkens, HG | 1 |
| Bakker, A | 1 |
| Sturmans, F | 1 |
| Urquhart, J | 1 |
| Fournier, P | 1 |
| Pacouret, G | 1 |
| Charbonnier, B | 1 |
| Toivonene, L | 1 |
| Hey, JA | 2 |
| del Prado, M | 2 |
| Kreutner, W | 2 |
| Egan, RW | 2 |
| Ng, PW | 1 |
| Chan, WK | 1 |
| Chan, TY | 1 |
| Feroze, H | 1 |
| Suri, R | 1 |
| Silverman, DI | 1 |
| Ishizaki, T | 1 |
| Usuda, K | 1 |
| Roberts, DJ | 1 |
| Llenas, J | 1 |
| Sherwood, J | 1 |
| Spence, JD | 1 |
| June, RA | 1 |
| Nasr, I | 1 |
| Rankin, AC | 1 |
| González, MA | 1 |
| Estes, KS | 1 |
| Pasco, J | 1 |
| DuBuske, LM | 1 |
| Pratt, C | 1 |
| Mason, J | 1 |
| Russell, T | 1 |
| Reynolds, R | 1 |
| Ahlbrandt, R | 1 |
| Khilnani, G | 1 |
| Remeysen, P | 1 |
| Shaikh, WA | 1 |
| Grzelewska-Rzymowska, I | 1 |
| Pietrzkowicz, M | 1 |
| Górska, M | 1 |
| Batey, AJ | 1 |
| Coker, SJ | 1 |
| Krasner, LM | 1 |
| Zimmermann, M | 1 |
| Duruz, H | 1 |
| Guinand, O | 1 |
| Broccard, O | 1 |
| Levy, P | 1 |
| Lacatis, D | 1 |
| Bloch, A | 1 |
| MacConnell, TJ | 1 |
| Stanners, AJ | 1 |
| McLeod, AA | 1 |
| Thorogood, S | 1 |
| Barnett, S | 1 |
| Warin, RP | 1 |
| Mathews, DR | 1 |
| McNutt, B | 1 |
| Okerholm, R | 1 |
| Flicker, M | 1 |
| McBride, G | 1 |
| Monahan, BP | 1 |
| Ferguson, CL | 1 |
| Killeavy, ES | 1 |
| Lloyd, BK | 1 |
| Troy, J | 1 |
| Cantilena, LR | 1 |
13 reviews available for terfenadine and Torsade de Pointes
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ER | 2003 |
Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.
Topics: Animals; Aza Compounds; Cisapride; Dogs; Drug Evaluation, Preclinical; Drug-Related Side Effects and | 2008 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
Long QT syndrome: reduced repolarization reserve and the genetic link.
Topics: Anti-Arrhythmia Agents; Disease Susceptibility; Female; Genotype; Histamine H1 Antagonists; Humans; | 2006 |
Cardiovascular toxicity of antihistamines.
Topics: Astemizole; Drug Interactions; Heart; Histamine H1 Antagonists; Humans; Terfenadine; Torsades de Poi | 1994 |
Torsades de pointes induced by erythromycin and terfenadine.
Topics: Drug Therapy, Combination; Electrocardiography; Erythromycin; Female; Humans; Lidocaine; Magnesium; | 1994 |
[Treatment with terfenadine and ketoconazole or itraconazole can cause torsades de pointes ventricular tachycardia].
Topics: Drug Interactions; Humans; Itraconazole; Ketoconazole; Terfenadine; Torsades de Pointes | 1993 |
Cardiac actions of antihistamines.
Topics: Animals; Astemizole; Cetirizine; Diphenhydramine; Drug Interactions; Histamine H1 Antagonists; Human | 1996 |
Strategic proposals to avoid drug interactions during drug development: a lesson from a terfenadine-related drug interaction.
Topics: Drug Design; Drug Interactions; Humans; Ketoconazole; Risk Assessment; Terfenadine; Torsades de Poin | 1996 |
[Drug induced arrhythmias].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Digitalis Glycosides; Electrocardiography, Ambulatory; | 1996 |
Pharmacokinetic overview of oral second-generation H1 antihistamines.
Topics: Astemizole; Blood-Brain Barrier; Cetirizine; Histamine H1 Antagonists; Humans; Loratadine; Structure | 1998 |
Second-generation antihistamines: the risk of ventricular arrhythmias.
Topics: Animals; Astemizole; Cytochrome P-450 Enzyme System; Drug Interactions; Electrocardiography; Heart; | 1999 |
[The effect of second generation histamine antagonists on the heart].
Topics: Animals; Area Under Curve; Astemizole; Butyrophenones; Electrocardiography; Heart; Histamine H1 Anta | 2001 |
2 trials available for terfenadine and Torsade de Pointes
| Article | Year |
|---|---|
Cardiovascular safety of fexofenadine HCl.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electrocardiography; Hista | 1999 |
The changing face of antihistamines and cardiac adverse drug reactions: a clinical perspective.
Topics: Cardiovascular Diseases; Drug Interactions; Electrocardiography; Erythromycin; Female; Histamine H1 | 2000 |
44 other studies available for terfenadine and Torsade de Pointes
| Article | Year |
|---|---|
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computationa | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes.
Topics: Animals; Atrioventricular Block; Chronic Disease; Disease Models, Animal; Drug Synergism; Ketoconazo | 2020 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electroc | 2007 |
Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine.
Topics: Action Potentials; Animals; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart; Hi | 2011 |
Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Biological Transport; Cells, C | 2012 |
Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.
Topics: Action Potentials; Animals; Cation Transport Proteins; Cell Line; DNA-Binding Proteins; Dogs; Electr | 2003 |
Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians.
Topics: Anti-Arrhythmia Agents; Antipsychotic Agents; Histamine H1 Antagonists; Humans; Long QT Syndrome; Ri | 2005 |
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Electrocardiography; ERG1 Potassium Channel; | 2006 |
Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.
Topics: Animals; Atrioventricular Node; Bradycardia; Catheter Ablation; Dogs; Dose-Response Relationship, Dr | 2006 |
[Extension of QT interval as a consequence of risk factor accumulation--case study].
Topics: Adult; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Drug Interactions; Female; Histamin | 2006 |
Interactions and drug-metabolizing enzymes.
Topics: Adolescent; Adult; Anti-Allergic Agents; Antidepressive Agents, Second-Generation; Antifungal Agents | 1995 |
Terfenadine increases the QT interval in isolated guinea pig heart.
Topics: Action Potentials; Analysis of Variance; Animals; Electrophysiology; Female; Guinea Pigs; Heart; In | 1995 |
Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Electrocardiography; Female; Humans; Liver Cirrhosis; Liver Neoplas | 1995 |
Torsade de pointes induced by terfenadine in a patient with long QT syndrome.
Topics: Adult; Electrocardiography; Female; Humans; Long QT Syndrome; Terfenadine; Torsades de Pointes; Urti | 1994 |
Additional causes of torsades de pointes.
Topics: Astemizole; Drug Overdose; Humans; Terfenadine; Torsades de Pointes | 1995 |
Torsades de pointes ventricular tachycardia associated with terfenadine and paracetamol self medication.
Topics: Acetaminophen; Aged; Aged, 80 and over; Electrocardiography; Heart Block; Humans; Male; Pacemaker, A | 1994 |
[Torsades de pointes caused by the association of terfenadine and erythromycin].
Topics: Drug Therapy, Combination; Erythromycin; Humans; Male; Middle Aged; Terfenadine; Torsades de Pointes | 1994 |
Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin.
Topics: Adolescent; Cardiac Output; Drug Interactions; Erythromycin; Female; Humans; Respiration, Artificial | 1994 |
Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia.
Topics: Adult; Drug Interactions; Electrocardiography; Female; Humans; Itraconazole; Risk Factors; Terfenadi | 1993 |
Is QT interval prolongation harmful? A regulatory perspective.
Topics: Astemizole; Butylamines; Electrocardiography; Humans; Terfenadine; Torsades de Pointes; Urinary Inco | 1993 |
Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Astemizole; Child; Child, Preschool; Drug Synergism; Dru | 1993 |
[A new cause of torsades de pointes: combination of terfenadine and troleandomycin].
Topics: Aged; Drug Synergism; Drug Therapy, Combination; Female; Humans; Terfenadine; Torsades de Pointes; T | 1993 |
Torsades de pointes after terfenadine-itraconazole interaction.
Topics: Adult; Drug Interactions; Female; Humans; Itraconazole; Ketoconazole; Terfenadine; Torsades de Point | 1993 |
Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes.
Topics: Animals; Butyrophenones; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; | 1996 |
Torsade de pointes during the concomitant use of terfenadine and cimetidine.
Topics: Cimetidine; Drug Interactions; Electrocardiography; Enzyme Inhibitors; Female; Humans; Middle Aged; | 1996 |
Torsades de pointes from terfenadine and sotalol given in combination.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Electrocardiography; Female; H | 1996 |
Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig.
Topics: Animals; Antifungal Agents; Butyrophenones; Disease Models, Animal; Drug Interactions; Electrocardio | 1996 |
The guinea pig model for assessing cardiotoxic proclivities of second generation antihistamines.
Topics: Animals; Antifungal Agents; Butyrophenones; Cats; Disease Models, Animal; Drug Interactions; Guinea | 1996 |
Drug interactions with grapefruit: whose responsibility is it to warn the public?
Topics: Anti-Allergic Agents; Anti-Asthmatic Agents; Citrus; Food-Drug Interactions; Humans; Pharmacology; S | 1997 |
Torsades de pointes with terfenadine ingestion.
Topics: Emergencies; Histamine H1 Antagonists; Humans; Male; Middle Aged; Terfenadine; Torsades de Pointes | 1997 |
Non-sedating antihistamines and cardiac arrhythmia.
Topics: Drug Interactions; Histamine H1 Antagonists; Humans; Nonprescription Drugs; Rhinitis, Allergic, Seas | 1997 |
What has the patient been taking?
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chlorothiazide; Cimetidine; Diagnosis, Differential; | 1998 |
Terfenadine should be withdrawn from clinical use.
Topics: Drug Interactions; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfenad | 1999 |
Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Anesthesia; Animals; Anti-Arrhythmi | 2000 |
Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.
Topics: Animals; Antimalarials; Disease Models, Animal; Electrocardiography; Histamine Antagonists; Male; Ph | 2002 |
Terfenadine use associated with ventricular dysrhythmias.
Topics: Arrhythmias, Cardiac; Electrocardiography; Humans; Terfenadine; Torsades de Pointes | 1992 |
Torsades de Pointes after treatment with terfenadine and ketoconazole.
Topics: Adult; Cardiac Pacing, Artificial; Dermatomycoses; Drug Therapy, Combination; Electrocardiography, A | 1992 |
Torsades de pointes complicating treatment with terfenadine.
Topics: Benzhydryl Compounds; Female; Histamine H1 Antagonists; Humans; Middle Aged; Terfenadine; Torsades d | 1991 |
Torsades de pointes complicating treatment with terodiline.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Histamine H1 Antagonists; Humans; Terfenadine | 1991 |
Torsades de pointes complicating treatment with terfenadine.
Topics: Benzhydryl Compounds; Histamine H1 Antagonists; Humans; Terfenadine; Torsades de Pointes | 1991 |
Torsades de pointes occurring in association with terfenadine use.
Topics: Drug Interactions; Electrocardiography; Humans; Ketoconazole; Terfenadine; Torsades de Pointes | 1991 |
Torsades de pointes occurring in association with terfenadine use.
Topics: Adult; Benzhydryl Compounds; Drug Interactions; Female; Histamine H1 Antagonists; Humans; Ketoconazo | 1990 |